Loading...
Nivolumab — Export Intelligence Report
2025-Q4 · TransData Nexus
PHARMA TRADE INTELLIGENCE
INDIA EXPORT INTELLIGENCE REPORT
Nivolumab
2025-Q4
Comprehensive analysis of India’s nivolumab export trade — suppliers, buyers, prices, routes, and every shipment record.
9
Shipments
$341K
Trade Value
5
Suppliers
6
Buyers
5
Countries
Scan for online report
Talk to our analyst: +91 95950 78788
https://transdatanexus.com/pharmaceutical/nivolumab
01
PART I — OVERVIEW
Executive Summary
At-a-glance KPIs, key findings, and strategic positioning of India’s nivolumab trade — 2025-Q4
KEY TAKEAWAY
Nivolumab 2025-Q4 exports total $341.3K across 5 countries, with DRREDDYS LABORATORIES LTD commanding 85.2% market share.
TOTAL SHIPMENTS
9
2025-Q4
EXPORT VALUE
$341.3K
FOB USD
TOTAL QUANTITY
698
units shipped
INDIAN SUPPLIERS
5
unique exporters
GLOBAL BUYERS
6
unique importers
DESTINATIONS
5
countries
MEDIAN UNIT PRICE
$653.06
per unit
TOP-5 SHARE
100.0%
of total USD
BRANDED SHARE
44.4%
4 shipments
DOSAGE FORMS
3
product types
6 KEY FINDINGS
1
DRREDDYS LABORATORIES LTD is India's #1 Nivolumab exporter with $290.8K (85.2% market share).→ §5, Indian Supplier Rankings
2
Nivolumab reached 5 countries, with Russia as the top destination ($290.8K).→ §4, Global Destination Map
3
Market concentration is high (HHI: 7478) — top 5 suppliers control 100.0% of exports.→ §5, Indian Supplier Rankings
4
100.0% of buyers (6 of 6) source from a single Indian supplier — potential poaching opportunities.→ §6, Global Buyer Rankings
5
Injection dominates (92.6%) across 3 dosage forms.→ §7, Price Benchmarks
6
5 countries have ≤5 Indian suppliers — easy-entry markets for SME exporters.→ §9, Strategic Opportunities
WHO THIS REPORT IS FOR
S SUPPLIERS (Indian pharma exporters)
- See which buyers your competitors are shipping to, at what price, through which ports
- Identify buyers that are single-sourced (poaching opportunities)
- Benchmark your pricing and catalog vs the Top 25
B BUYERS (global importers)
- Discover which Indian exporters supply this product and what they sell
- Benchmark the price you are paying vs the market median by country and dosage
- Identify alternative suppliers with proven exports to similar destinations
Figure 1.1 DRREDDYS LABORATORIES LTD leads in volume — how do 5 exporters compare on price × volume?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Every bubble is one Indian nivolumab exporter. X-axis = shipment count; Y-axis = average unit price; bubble size = total revenue. Dashed lines split at the median — exporters in the top-right (Bulk Leaders) combine high volume with premium pricing.
HOW TO READ THIS REPORT
60 seconds
Scan this page — KPIs, thesis, flagship chart, top findings
5 minutes
Read every Key Takeaway line across §1–§9
30 minutes
Read sections tagged for your role ([S] or [B]) end-to-end
In depth
Drill into §10 for your country · supplier / buyer directories at end
02
PART I — OVERVIEW
About This Report
Data sources, methodology, trust signals, and what this Nivolumab report covers
KEY TAKEAWAY
Every figure in this report is grounded in real commercial nivolumab trade records. Data comes from official customs filings and public trade sources, runs through a multi-layer quality process, and lands in a clean, consistent report you can rely on.
S FOR SUPPLIERS
Every competitor benchmark, market share figure, and buyer list in this report comes from verified commercial shipments — not surveys or estimates. Use them with confidence when planning your next pitch.
B FOR BUYERS
Every supplier profile, price benchmark, and trade route in this report reflects what that supplier actually ships — real volumes, real destinations, real prices. Use them to qualify and compare Indian nivolumab suppliers.
§2.1 Reporting parameters · the scope of this 2025-Q4 Nivolumab India trade report
Product scope
Nivolumab
All variants merged — branded and generic formulations of nivolumab
Time period
2025-Q4
October, November, December 2025 — a single-quarter snapshot
Data sources
Official & public trade records
Government customs filings, public trade databases and licensed commercial feeds
Geography
India origin → global
Indian sea and air ports shipping to destination markets worldwide
Currency
USD (FOB)
Declared Free-on-Board value at the Indian port of loading
Shipments analysed
9
Every commercial nivolumab trade record in the period, aggregated and deduplicated
§2.2 Our quality process · Figure 2.1
Figure 2.1 From raw trade records to a clean report — the four quality pillars.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Raw trade data (left) flows through four quality checks — source verification, format standardisation, entity matching, and deduplication — to produce the clean, reliable data (right) behind every chart and table in this report.
§2.3 Trust signals · what you can rely on in the numbers you read
DATA COVERAGE
10M+
Pharmaceutical trade records across the full TransData Nexus platform.
COUNTRIES
150+
Origin and destination countries covered in the global pharma trade database.
DATA ACCURACY
99.9%
Validation rate on core fields — supplier, buyer, product, quantity, value.
UPDATE FREQUENCY
Daily
Platform refresh cadence. This report is a snapshot from the same live data.
§2.4 Limitations · what the data does and does not tell you
WHAT THIS DATA DOES AND DOES NOT SAY
- Prices are at the Indian port of loading (FOB), not the final delivered cost in the destination country. Freight, insurance, import duty and local margin are not included.
- This is a single-quarter snapshot. Multi-quarter trends, year-over-year growth and historical comparisons are available on the full platform.
- A small number of records have incomplete transport mode or destination port fields; these appear blank in the shipment register but are still counted in totals.
- This report is a commercial intelligence tool, not a legal audit. For high-stakes decisions, cross-reference with the underlying trade records via the full platform.
03
PART II — MARKET STRUCTURE
Quarterly Trade Overview
Monthly trends, regional performance, and ranking shifts — 2025-Q4
KEY TAKEAWAY
2025-Q4 followed a mixed: Oct $290.8K, Nov $50.4K, Dec $80. Shipment counts were mixed across the quarter.
S FOR SUPPLIERS
Track which months your competitors were most active, which destinations rose or fell, and whether the Nov dip hit your segment. The bump charts show rank movement — watch for rivals climbing past you.
B FOR BUYERS
Identify whether your current Indian supplier maintained steady shipments through the quarter, or whether they pulled back. Steady suppliers during dips signal reliable partnerships.
1
$290.8K
Oct USD
3 shipments
2
$50.4K
Nov USD
-82.7% MoM
3
$80
Dec USD
-99.8% MoM
4
Mixed
Q4 growth shape
Oct → Nov → Dec
Fig 3.1 Nov dipped 82.7% in USD but shipment count kept climbing.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = monthly USD. Orange line = shipment count. When bars drop but line rises, average shipment value fell. Insight: Oct opened at $291K, making it the strongest month by value.
Fig 3.2 Q4 cumulative USD reached $341K.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The curve shows the running total across the quarter. A steeper slope means that month contributed more revenue. Insight: The curve’s steepest section reveals which month drove the most trade value.
Fig 3.3 $240K dip in Nov, $50K decline in Dec.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = absolute monthly value. Red = month-over-month loss; green = gain. Insight: Nov’s dip was fully recovered by Dec.
Fig 3.4 Regional breakdown by month — which corridors swung most?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each coloured layer is one destination region. Layer height = USD in that month. Insight: The top region contributed the most, while the smallest region had the least volume.
§3.1 Monthly summary
| Oct | $291K | 3 shipments |
| Nov | $50K | 5 shipments |
| Dec | $80 | 1 shipments |
| Q4 Total | $341K | 9 shipments |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 3.5 Top 5 destination countries by monthly USD rank — who’s rising?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a country’s monthly rank. Lines crossing = rank swaps. Insight: Saint Kitts and Nevis held #1 throughout the quarter.
Fig 3.6 Top 5 Indian exporters by monthly USD rank.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a supplier’s monthly rank. Flat = stable position; crossing = rank change. Insight: FINDLIFE PHARMACEUTICAL maintained its leading position.
04
PART II — MARKET STRUCTURE
Global Destination Map
Which countries import nivolumab from India, how much they buy, and who supplies each market
KEY TAKEAWAY
Russia absorbs 85.2% of India’s 2025-Q4 nivolumab trade ($290.8K). Beyond the top 5 destinations, 5 countries have fewer than 5 Indian suppliers each — white-space markets where new entrants face minimal competition. Americas has 2 destination countries, the widest regional diversity.
S FOR SUPPLIERS
Use the flow map and lanes table to see which destinations your competitors dominate. For small and mid-size suppliers: look beyond the leading markets — the 5 countries in the long tail have fewer than 5 Indian suppliers each and low competitive barriers.
B FOR BUYERS
Find your country on the map to see how much nivolumab India ships to your market, who the top suppliers are, and whether you’re in a concentrated or competitive corridor.
Asia
$50K
14.8% of trade
1 countries · 4 shipments
Europe
$291K
85.2% of trade
2 countries · 3 shipments
Americas
$114
0.0% of trade
2 countries · 2 shipments
Fig 4.1 Russia is the #1 corridor ($291K) — 5 flow arcs from India radiate across 3 continents.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The world map shows every country colored by how much Indian nivolumab it receives (light = low, dark = high). Orange arcs radiate from India to the top 5 destinations; arc thickness = USD value. All destinations are labeled with country name + USD.
§4.1 Top 5 bilateral trade lanes (India → destination) with top Indian suppliers
| # | Destination | Total USD | Ships | #1 Indian supplier | USD | #2 Indian supplier | USD | #3 Indian supplier | USD |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Russia | $291K | 2 | DRREDDYS LABORATORIES LTD | $291K | — | — | — | — |
| 2 | Maldives | $50K | 4 | MC PHARMA DISTRIBUTORS | $50K | — | — | — | — |
| 3 | Saint Kitts and Nevis | $80 | 1 | FINDLIFE PHARMACEUTICAL | $80 | — | — | — | — |
| 4 | United States | $34 | 1 | ENZENE BIOSCIENCES LTD | $34 | — | — | — | — |
| 5 | United Kingdom | $8 | 1 | MSN LABORATORIES PVT LTD | $8 | — | — | — | — |
Table 4.1 — Top 5 destination countries ranked by trade value, with the largest Indian suppliers for each market.
Fig 4.2 Asia leads at 14.8% of USD — but Russia is the single largest market.
Region → country treemap
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Column width = region USD share. Within each column, cells are stacked by country, height = share within region.
§4.2 Destination concentration
85.2%
#1 country share
Russia alone
100.0%
Top 5 share
5 of 5 countries
100.0%
Top 15 share
Long tail of -10 countries = 0.0%
HHI 7478
Destination HHI
Highly concentrated
5
Countries served
Global pharma reach from India
2
Americas countries
Widest regional diversity
Source: TransData Nexus trade data platform
05
PART III — WHO’S IN THIS MARKET
Indian Supplier Rankings & Profiles
5 Indian exporters ranked by value — profiles, portfolios, and competitive intelligence
KEY TAKEAWAY
DRREDDYS LABORATORIES LTD ($290.8K, 85.2% share) and MC PHARMA DISTRIBUTORS ($50.4K) together control 100.0% of India’s 2025-Q4 nivolumab trade. The top 5 suppliers hold 100.0%. 5 companies shipped at least once.
S FOR SUPPLIERS
Find your rank, your competitors’ ranks, and the gap in USD/share between you. The profile pages show each top supplier’s buyer portfolio, dosage mix and route map — your competitive-intelligence toolkit.
B FOR BUYERS
Find potential Indian nivolumab suppliers ranked by size, catalog breadth and destination reach. The profile pages reveal which suppliers have proven trade lanes to your region.
Fig 5.1 DRREDDYS LABORATORIES LTD leads by $240K over MC PHARMA DISTRIBUTORS — top 5 Indian exporters ranked by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian supplier ranked by USD. The (#N) shows their rank by shipment count — mismatches reveal pricing strategy. Insight: DRREDDYS LABORATORIES LTD is #1 by value but #2 by volume.
Fig 5.2 MC PHARMA DISTRIBUTORS also leads by shipment count (4) but ranking shifts for volume-heavy players
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same suppliers re-ranked by shipment count. The (#N) shows their rank by USD value. Insight: DRREDDYS LABORATORIES LTD moves from #2 by volume to #1 by value — fewer but higher-value shipments.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — Archetypes & Concentration
How India’s 5 nivolumab suppliers split into strategic segments
KEY TAKEAWAY
2 suppliers (25%) generate 100.0% of total trade value. The market splits into four archetypes: Market Leaders, High-Value specialists, Volume players, and a long tail.
Fig 5.3 DRREDDYS LABORATORIES LTD and MC PHARMA DISTRIBUTORS sit in the leaders zone — high volume AND high value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble is one Indian supplier. X-axis = shipment count (log scale); Y-axis = total USD value (log scale); bubble size = revenue. Blue dashed lines split at the median. Market Leaders (top-right) combine high volume with high value. Premium Niche (top-left) ship fewer but higher-value consignments. Volume Players (bottom-right) compete on quantity. Long-Tail (bottom-left) are small or occasional exporters. Conclusion: the log scale reveals clear strategic clusters — use this map to identify where your company sits relative to competitors.
Fig 5.4 25% of suppliers = 100.0% of USD — classic concentration.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Top bar = supplier %, bottom bar = USD %. The gap = market concentration.
Product variety — how many formulations each supplier ships
| # | Supplier | Dosage forms | Countries | USD |
|---|---|---|---|---|
| 1 | MC PHARMA DISTRIBUTORS | 3 | 1 | $50K |
| 2 | DRREDDYS LABORATORIES LTD | 1 | 1 | $291K |
| 3 | FINDLIFE PHARMACEUTICAL | 1 | 1 | $80 |
| 4 | ENZENE BIOSCIENCES LTD | 1 | 1 | $34 |
| 5 | MSN LABORATORIES PVT LTD | 1 | 1 | $8 |
Table 5.1 — The more dosage forms a supplier ships, the more versatile their manufacturing capability.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — India Origin Geography & Concentration
Which Indian cities and states are the nivolumab manufacturing hubs
KEY TAKEAWAY
Medchel Malkajgiri Dist and Chennai together account for $316K of India’s 2025-Q4 nivolumab trade.
Fig 5.5 Medchel Malkajgiri Dist (1 exporters, $291K) and Chennai (1 exporters, $25K) are India’s nivolumab capitals.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Orange bubbles mark major pharma hub cities; bubble size = USD value. Every hub labeled.
§5.1 Supplier concentration metrics
100.0%
Top 5 share
5 of 5 suppliers
100.0%
Top 5 share
5 of 5 suppliers
100.0%
Top 25% share
2 suppliers = 100% USD
HHI 7478
Supplier HHI
Concentrated
5
Total suppliers
shipped Nivolumab in 2025-Q4
6+ cities
Indian hubs
Medchel Malkajgiri Dist and Chennai lead
§5.2 Coming next: 0 exporter deep-dive profiles
Each of the top 0 suppliers gets a dedicated 2-page profile with:
- 6 KPI cards — trade value, shipments, countries, buyers, avg ship value, branded share
- Dosage form breakdown — what formulations they ship
- Monthly trend — Oct / Nov / Dec trajectory
- Trade flow map — supplier → country → importer connections
- Buyer portfolio with lock-in analysis
SUPPLIER PROFILES IN THIS REPORT
06
PART III — WHO’S IN THIS MARKET
Global Buyer Rankings & Intelligence
6 importers across 5 countries — who is buying Indian nivolumab and how much
KEY TAKEAWAY
The demand side is dramatically more fragmented than supply: the top 4 importers together hold only 92.6% of total USD. 100% of buyers source from a single Indian supplier — a vast pool of lock-in candidates.
S FOR SUPPLIERS
Find the importers buying from your competitors. The rankings reveal who has volume, who pays well, and who sources from multiple Indian suppliers (potential pitch targets).
B FOR BUYERS
See where you rank among global importers of Indian nivolumab. Compare your USD and shipment count against peers in your country and dosage segment.
Fig 6.1 COREX LLC is the #1 importer at $291K (85.2%) — top 4 by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one global importer ranked by USD.
Fig 6.2 Re-ranked by shipment count — compare with Fig 6.1 for divergences
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same 4 importers re-ranked by shipment count.
§6.1 Sourcing diversity — how many Indian suppliers does each buyer use?
100%
Single-source
6 buyers rely on exactly 1 Indian supplier
0%
Dual-source
0 buyers use 2 Indian suppliers
0%
Multi-source (3–4)
0 buyers diversified across 3–4
0%
Broad-source (5+)
0 buyers with 5+ Indian suppliers
06
PART III — WHO’S IN THIS MARKET
Single-Source Buyers & Price Benchmark
Lock-in opportunities grouped by country + where each buyer sits on the price spectrum
KEY TAKEAWAY
These importers source nivolumab from exactly one Indian supplier. For each one, the table shows the incumbent, price, and dosage.
S FOR SUPPLIERS
This is your target list. Each row is a buyer locked into one competitor. Offer 5–10% better pricing to win the second-source slot.
B FOR BUYERS
If you see your company here, you are fully dependent on one Indian supplier. Consider qualifying a second source.
§6.2 Single-source lock-in by country
Russia 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| COREX LLC | DRREDDYS LABORATORIE… | $291K | $460.110 | Injection |
Maldives 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| STATE TRADING ORGANIZA… | MC PHARMA DISTRIBUTORS | $25K | $1K | Injection |
United States 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| RUTGERS UNIVERSITY | ENZENE BIOSCIENCES LTD | $34.016 | $11.339 | Solution |
United Kingdom 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| SARTORIUS STEDIM BIOOU… | MSN LABORATORIES PVT… | $8.192 | $1.170 | Solution |
§6.3 Price positioning — top 4 importers
| # | Importer | Country | USD | $/ship | Tier |
|---|---|---|---|---|---|
| 1 | COREX LLC | Russia | $291K | $145K | Premium |
| 2 | STATE TRADING ORGANI… | Maldives | $25K | $13K | Budget |
| 3 | RUTGERS UNIVERSITY | United States | $34.016 | $34.000 | Budget |
| 4 | SARTORIUS STEDIM BIO… | United Kingdom | $8.192 | $8.000 | Budget |
06
PART III — WHO’S IN THIS MARKET
Market Relationship Map
The top 5 × 4 supplier ↔ buyer network as a circular flow diagram
Fig 6.3 DRREDDYS LABORATORIES LTD → COREX LLC is the strongest relationship.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left semicircle = top 5 Indian suppliers; right = top 4 global buyers. Arc length = total USD; colored ribbons = individual relationships, thickness = USD value. Insight: follow the thickest ribbons to identify the dominant trading pairs.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
How Indian nivolumab prices vary by supplier, country and dosage form
KEY TAKEAWAY
Nivolumab prices span 897× ($1.17 → $1049.51). The coefficient of variation is 0.82. Dosage form, not destination, is the primary price driver.
S FOR SUPPLIERS
Use the box plot to see where your product sits on the price spectrum. The tornado chart shows exactly where you sit relative to the market median.
B FOR BUYERS
Use this section to benchmark the price you pay against the market. The percentile strip tells you if your current supplier is charging you premium, mid-market or budget rates.
§7.1 Price distribution · Table 7.1
| Statistic | Value | Interpretation |
|---|---|---|
| Min | $1.17 | Lowest observed unit price |
| P5 | $4.72 | 5th percentile |
| P25 | $11.34 | 25th percentile (Q1) |
| Median | $653.06 | 50th percentile (Q2) |
| P75 | $1.0K | 75th percentile (Q3) |
| P95 | $1.0K | 95th percentile |
| Max | $1.0K | Highest observed unit price |
| Mean | $571.18 | Arithmetic average |
| CV | 82% | Coefficient of variation (std/mean) |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 7.1 MC PHARMA DISTRIBUTORS prices at $1K/unit vs market median $653.06.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar shows one supplier’s average unit price relative to the market median (dashed line). Red = above median (premium), green = below (budget).
COMMODITY KINGS
high volume · low unit price
Bulk API/tablet. Largest absolute USD despite lowest per-unit prices. e.g. FINDLIFE PHARMACEUTICAL Sourcing: best for cost-driven procurement.
BULK LEADERS
high volume · premium price
Branded-generic leaders, above-median pricing. e.g. DRREDDYS LABORATORIES LTD Sourcing: hardest to displace; compete on relationship.
LONG-TAIL
low volume · low unit price
Spot/opportunistic players. Sourcing: first to approach for new tenders.
PREMIUM NICHE
low volume · premium price
Sterile injectables and infusions. Hospital-grade. Sourcing: expect 10× price vs tablet.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
Outlier forensics and the procurement cheat sheet — what to expect to pay by country × dosage
KEY TAKEAWAY
Extreme prices are real: the highest are specialty/sterile formulations; the lowest are bulk API. The cheat sheet matrix is the take-home reference for procurement teams.
§7.2 Outlier forensics — top 9 highest and 9 lowest unit prices
↑ TOP 10 HIGHEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Nov 2025 | MC PHARMA DISTRI… | Maldives | Injection | 12 | $13K | $1K | Sterile formulation premium |
| Nov 2025 | MC PHARMA DISTRI… | Maldives | Other | 12 | $13K | $1K | Specialty / small-batch |
| Nov 2025 | MC PHARMA DISTRI… | Maldives | Injection | 12 | $13K | $1K | Sterile formulation premium |
| Nov 2025 | MC PHARMA DISTRI… | Maldives | Solution | 12 | $13K | $1K | Specialty / small-batch |
| Oct 2025 | DRREDDYS LABORAT… | Russia | Injection | 316 | $206K | $653.06 | Sterile formulation premium |
| Oct 2025 | DRREDDYS LABORAT… | Russia | Injection | 316 | $84K | $267.16 | Sterile formulation premium |
| Nov 2025 | ENZENE BIOSCIENC… | United States | Solution | 3 | $34.02 | $11.34 | Specialty / small-batch |
| Dec 2025 | FINDLIFE PHARMAC… | Saint Kitts and Nevis | Injection | 8 | $80.36 | $10.04 | Sterile formulation premium |
| Oct 2025 | MSN LABORATORIES… | United Kingdom | Solution | 7 | $8.19 | $1.17 | Specialty / small-batch |
↓ TOP 10 LOWEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Oct 2025 | MSN LABORATORIES… | United Kingdom | Solution | 7 | $8.19 | $1.17 | Specialty / small-batch |
| Dec 2025 | FINDLIFE PHARMAC… | Saint Kitts and Nevis | Injection | 8 | $80.36 | $10.04 | Sterile formulation premium |
| Nov 2025 | ENZENE BIOSCIENC… | United States | Solution | 3 | $34.02 | $11.34 | Specialty / small-batch |
| Oct 2025 | DRREDDYS LABORAT… | Russia | Injection | 316 | $84K | $267.16 | Sterile formulation premium |
| Oct 2025 | DRREDDYS LABORAT… | Russia | Injection | 316 | $206K | $653.06 | Sterile formulation premium |
| Nov 2025 | MC PHARMA DISTRI… | Maldives | Injection | 12 | $13K | $1K | Sterile formulation premium |
| Nov 2025 | MC PHARMA DISTRI… | Maldives | Solution | 12 | $13K | $1K | Specialty / small-batch |
| Nov 2025 | MC PHARMA DISTRI… | Maldives | Injection | 12 | $13K | $1K | Sterile formulation premium |
| Nov 2025 | MC PHARMA DISTRI… | Maldives | Other | 12 | $13K | $1K | Specialty / small-batch |
§7.3 Procurement cheat sheet — median USD/unit by country × dosage
Fig 7.2 Median unit price by country × dosage form — darker cells = higher prices.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each cell shows the median price per unit for that country-dosage combination. Dark blue = expensive, light = cheap. Blank cells = no shipments in that combination.
NEGOTIATION RANGE
Use each cell value as the anchor price. Typical dynamics:
- Budget buyer: anchor − 10–15% (floor = cost + freight)
- Mid-market: anchor ± 5–10%
- Premium/tender: anchor + 10–25% (regulated, quality premium)
- Injection/infusion: always 4–10× the tablet price
KEY TAKEAWAYS
- Dosage form is the #1 price driver, not destination
- Light cells = easy-entry markets for small suppliers
- Dark cells = premium markets requiring regulatory investment
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Which Indian ports ship nivolumab, which global ports receive it, and which corridors are high-value vs bulk
KEY TAKEAWAY
Nivolumab leaves India through 4+ ports. The top 5 (HYDERABAD AIR, CHENNAI AIR, DELHI AIR) handle 100.0% of total USD. AIR moves 100% of shipments.
S FOR SUPPLIERS
Use the dumbbell to classify your port as high-value hub or bulk workhorse. Note the short-sea routes — Bangladesh, Sri Lanka, Myanmar and East Africa are the easiest logistics corridors for first-time exporters.
B FOR BUYERS
Use the destination port ranking to find which Indian ports serve your market. The lead-time estimates tell you what transit time to expect.
Fig 8.1 HYDERABAD AIR handles $291K — top 4 Indian origin ports by trade value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian port. Bar length = USD value. The largest ports handle the majority of trade.
Fig 8.2 MOSCOW DOMODEDOVO is the #1 global destination port — top 5 by USD value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one destination port worldwide. Bar length = USD value received from India.
§8.1 Reference transit times for key India → global corridors
| Route | Mode | Transit time | Notes |
|---|---|---|---|
| NHAVA SHEVA SEA (JNPT) → US East Coast | Sea | 22–28 days | Via Suez; 2–3 transshipments typical |
| NHAVA SHEVA SEA (JNPT) → Lagos (Nigeria) | Sea | 18–24 days | Direct liner service available |
| MUMBAI AIR (SAHAR) → New York JFK | Air | 3–5 days | Direct cargo; cold-chain available |
| MUNDRA SEA → Rotterdam | Sea | 20–26 days | Via Suez; Hamburg also served |
| HYDERABAD AIR → London Heathrow | Air | 2–4 days | Pharma-grade cargo corridor |
| CHENNAI SEA → Chittagong (Bangladesh) | Sea | 7–12 days | Short-sea route; high frequency |
| RAXAUL → Birgunj (Nepal) | Road | 1–2 days | Land border crossing |
| NHAVA SHEVA SEA (JNPT) → Mombasa (Kenya) | Sea | 14–20 days | Direct or via Colombo hub |
Table 8.1 — Reference times based on standard shipping corridors. Air = 2–5 days; sea = 7–28 days; road = 1–2 days. Add 3–7 days for customs clearance at destination.
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Trade corridors — origin port to mode of transport to destination region
KEY TAKEAWAY
AIR dominates at 100% of shipments. The alluvial traces every dollar from Indian origin port through transport mode to destination region.
AIR
$341K
100.0% of USD · 100.0% of ships
Fig 8.3 The dominant corridor is HYDERABAD AIR → Air → Europe ($291K).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian origin ports. Middle = transport mode. Right = destination region. Ribbon thickness = USD value; color = mode. Follow the thickest ribbons to find the highest-value corridors.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market concentration, supply-chain risk, and the dependency patterns that signal where to act
KEY TAKEAWAY
Maldives is the most concentrated destination (HHI 10000, 1 suppliers). Saint Kitts and Nevis is the most competitive (HHI 10000).
S FOR SUPPLIERS
The HHI barbell shows where competitors have locked up a market (concentrated = poaching opportunity) vs where you must compete on quality (fragmented). The slope chart reveals who is gaining ground.
B FOR BUYERS
The HHI barbell tells you whether your country has enough supplier options. If concentrated (red zone), you have fewer alternatives.
Fig 9.1 Maldives (HHI 10,000) is the most concentrated — Maldives (HHI 10,000) is the most competitive.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
What is HHI? The Herfindahl-Hirschman Index measures how concentrated a market is among its suppliers. It ranges from 0 to 10,000. Below 1,500 (green zone) = many suppliers compete openly — healthy, competitive market with low risk. 1,500–2,500 (yellow zone) = a few suppliers hold significant share — moderate concentration. Above 2,500 (red zone) = one or two suppliers dominate the market — high risk for buyers who may lose supply, and hard to break into for new suppliers. Conclusion: 5 of 5 destination markets are concentrated (red zone). 0 are competitive (green zone). Buyers in red-zone markets should urgently qualify a second Indian supplier to reduce dependency risk.
§9.1 Single-source dependencies
| Buyer | Country | Sole supplier | USD | Ships | Risk |
|---|---|---|---|---|---|
| COREX LLC | Russia | DRREDDYS LABORAT… | $291K | 2 | HIGH |
| STATE TRADING ORGANI… | Maldives | MC PHARMA DISTRI… | $25K | 2 | MEDIUM |
| RUTGERS UNIVERSITY | United States | ENZENE BIOSCIENC… | $34 | 1 | MEDIUM |
| SARTORIUS STEDIM BIO… | United Kingdom | MSN LABORATORIES… | $8 | 1 | MEDIUM |
Conclusion: 4 buyers depend on exactly one Indian supplier, representing $316K in trade. For suppliers: each row is a competitor’s locked-in customer you can target.
§9.2 Multi-source resilience
| Buyer | Country | Suppliers | USD | Dominant | Resilience |
|---|
Conclusion: 0 of these buyers have HIGH resilience (3+ active suppliers). These are the hardest accounts to win but safest partners for long-term contracts.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market entry playbook and risk landscape by destination country
KEY TAKEAWAY
15 target markets with specific entry approaches. Large suppliers: focus on regulated Tier 1 markets. Small/mid-size: start with Tier 2–3 (low barrier, growing demand).
§9.3 Sourcing recommendations · Table 9.1
| Country | Tier | Lead | Price | Risk | Entry approach |
|---|---|---|---|---|---|
| Russia | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Maldives | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Saint Kitts and Nevis | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| United States | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| United Kingdom | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
For suppliers: Tier 1 markets (US, UK, France) require regulatory investment but offer premium pricing. Tier 3 markets (emerging) have low barriers — ideal for first-time exporters. For buyers: Use the price band and lead time to benchmark your current supplier’s terms.
Fig 9.2 0 markets in the Growth Opportunity zone (competitive + growing). 5 in Fragile Dependency (concentrated + shrinking).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble = one destination. X-axis = HHI (concentration). Y-axis = growth %. Bubble size = USD. Green zone (top-left) = Growth Opportunity — competitive markets that are growing, best for new entrants. Red zone (bottom-right) = Fragile Dependency — concentrated + shrinking, high supply-chain risk. Conclusion: Key markets are the top growth opportunities.
09
PART V — ACTION
Action Plan & Easy-Entry Markets
12 prioritised actions + 5 low-competition destination countries for small & mid-size suppliers
KEY TAKEAWAY
Quick Wins: execute this quarter. Big Bets: plan for next 6–12 months. Plus 5 countries with ≤5 Indian suppliers — the best entry points for SMEs.
S
FOR SUPPLIERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A1 | Pitch top single-source buyer in Russia | This Q | HIGH |
| A2 | Offer alternative to top multi-source buyer | This Q | HIGH |
| A3 | Audit Maldives lock-ins (HHI 10000) | This Q | MED |
| A5 | Enter Russia (1 suppliers) | This Q | HIGH |
| A6 | Enter Maldives (1 suppliers) | This Q | MED |
| A8 | Build Maldives distribution | 6–12m | HIGH |
| A9 | Bundle injection/infusion catalog for premium markets | 6–12m | MED |
B
FOR BUYERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A4 | Monitor rising exporters (climbers) | This Q | MED |
| A7 | Register for Russia tenders | 6–12m | HIGH |
| A10 | Track quarterly HHI shifts across key destinations | This Q | LOW |
| A11 | Map competitor buyer portfolios quarterly | This Q | MED |
| A12 | Qualify second source for single-source buyers | This Q | MED |
§9.4 Easy-entry markets — 5 countries with ≤5 Indian suppliers
| # | Country | Region | Suppliers | Q4 USD | Growth | Barrier | Why this is easy |
|---|---|---|---|---|---|---|---|
| 1 | Russia | Other | 1 | $291K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 2 | Maldives | Asia | 1 | $50K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 3 | Saint Kitts and Nevis | Other | 1 | $80 | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 4 | United States | Other | 1 | $34 | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 5 | United Kingdom | Other | 1 | $8 | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
This report covers 9 2025-Q4 Nivolumab shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/nivolumab
10
PART VI — EVIDENCE REGISTER
Comprehensive Shipment Records by Region
Authoritative source behind all analytics in this report — every shipment appears exactly once
KEY TAKEAWAY
This section contains every one of the 9 2025-Q4 nivolumab shipments, organised by Region → Exporter → Shipment rows. No row is duplicated.
S FOR SUPPLIERS
Jump to any destination country to see exactly who your competitors ship to, what they charge, through which port, and how often.
B FOR BUYERS
Jump to your country to see every Indian nivolumab shipment that arrived in 2025-Q4: supplier, price, dosage, port.
§10.1 Global totals
SHIPMENTS
9
across all regions
TOTAL USD
$341K
2025-Q4 FOB value
UNITS
698
tablets, capsules, etc.
SUPPLIERS
5
Indian exporters
BUYERS
6
global importers
COUNTRIES
5
destinations
§10.2 Regional breakdown
§10.3 Key insights from the data
Asia is the largest region at $50K (14.8%), spanning 1 countries.
5 Indian suppliers shipped to 6 buyers across 5 countries — average shipment value $38K.
Top 0 markets: .
Every row below is real customs data — date, importer, dosage, brand, quantity, unit price, total USD, origin port, destination port, and transport mode.
§10.4 How to read a country page
1
6 KPI cards — shipments, USD, qty, exporters, importers, avg unit price.
2
4 mini-lists — top exporters, importers, dosages, monthly trend.
3
Shipment register — every row grouped by exporter. No row is duplicated or omitted.
10
PART VI — DRILL-DOWN · ASIA
Region: Asia
1 countries · 4 shipments · $50K · 1 Indian suppliers · 2 buyers
SHIPMENTS
4
USD
$50K
COUNTRIES
1
SUPPLIERS
1
BUYERS
2
HHI
10,000
concentrated
Top 1 destination countries in Asia
1
Maldives (100.0%)
$50K
Top 1 Indian suppliers into Asia
1
MC PHARMA DISTRIBUTORS
$50K
Top 1 Asia importers
1
STATE TRADING ORGANIZATION PLC · Maldives
$25K
Top 3 dosage forms
1
Injection
$25K
2
Other
$13K
3
Solution
$13K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 0 | $0.0000 | — |
| Nov | 4 | $50K | $13K |
| Dec | 0 | $0.0000 | — |
Shipment register · 4 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — MC PHARMA DISTRIBUTORS · 4 shipments · $50K | |||||||||||
| 1 | Nov 2025 | STATE TRADING ORGANIZATION PLC | Maldives | Injection | 12 | PCS | $1K | $13K | CHENNAI AIR | MALE | AIR |
| 2 | Nov 2025 | STATE TRADING ORGANIZATION PLC | Maldives | Injection | 12 | PCS | $1K | $13K | CHENNAI AIR | MALE | AIR |
| 3 | Nov 2025 | UNKNOWN BUYER | Maldives | Solution | 12 | PCS | $1K | $13K | CHENNAI AIR | MALE | AIR |
| 4 | Nov 2025 | UNKNOWN BUYER | Maldives | Other | 12 | PCS | $1K | $13K | CHENNAI AIR | MALE | AIR |
10
PART VI — DRILL-DOWN · EUROPE
Region: Europe
2 countries · 3 shipments · $291K · 2 Indian suppliers · 2 buyers
SHIPMENTS
3
USD
$291K
COUNTRIES
2
SUPPLIERS
2
BUYERS
2
HHI
9,999
concentrated
Top 2 destination countries in Europe
1
Russia (100.0%)
$291K
2
United Kingdom (0.0%)
$8.19
Top 2 Indian suppliers into Europe
1
DRREDDYS LABORATORIES LTD
$291K
2
MSN LABORATORIES PVT LTD
$8.19
Top 2 Europe importers
1
COREX LLC · Russia
$291K
2
SARTORIUS STEDIM BIOOUTSOURCE LTD · United Kingdom
$8.19
Top 2 dosage forms
1
Injection
$291K
2
Solution
$8.19
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 3 | $291K | $97K |
| Nov | 0 | $0.0000 | — |
| Dec | 0 | $0.0000 | — |
Shipment register · 3 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — DRREDDYS LABORATORIES LTD · 2 shipments · $291K | |||||||||||
| 1 | Oct 2025 | COREX LLC | Russia | Injection | 316 | NOS | $267.16 | $84K | HYDERABAD AIR | MOSCOW DOMODEDOVO | AIR |
| 2 | Oct 2025 | COREX LLC | Russia | Injection | 316 | NOS | $653.06 | $206K | HYDERABAD AIR | MOSCOW DOMODEDOVO | AIR |
| SUPPLIER #2 — MSN LABORATORIES PVT LTD · 1 shipments · $8.19 | |||||||||||
| 3 | Oct 2025 | SARTORIUS STEDIM BIOOUTSOURCE LTD | United Kingdom | Solution | 7 | NOS | $1.17 | $8.19 | HYDERABAD AIR | LONDON METROPOLITAN | AIR |
10
PART VI — DRILL-DOWN · AMERICAS
Region: Americas
2 countries · 2 shipments · $114.37 · 2 Indian suppliers · 2 buyers
SHIPMENTS
2
USD
$114.37
COUNTRIES
2
SUPPLIERS
2
BUYERS
2
HHI
5,821
concentrated
Top 2 destination countries in Americas
1
Saint Kitts and Nevis (70.3%)
$80.36
2
United States (29.7%)
$34.02
Top 2 Indian suppliers into Americas
1
FINDLIFE PHARMACEUTICAL
$80.36
2
ENZENE BIOSCIENCES LTD
$34.02
Top 1 Americas importers
1
RUTGERS UNIVERSITY · United States
$34.02
Top 2 dosage forms
1
Injection
$80.36
2
Solution
$34.02
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 0 | $0.0000 | — |
| Nov | 1 | $34.02 | $34.02 |
| Dec | 1 | $80.36 | $80.36 |
Shipment register · 2 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — FINDLIFE PHARMACEUTICAL · 1 shipments · $80.36 | |||||||||||
| 1 | Dec 2025 | UNLISTED BUYER | Saint Kitts and Nevis | Injection | 8 | NOS | $10.04 | $80.36 | DELHI AIR | ST KITTS | AIR |
| SUPPLIER #2 — ENZENE BIOSCIENCES LTD · 1 shipments · $34.02 | |||||||||||
| 2 | Nov 2025 | RUTGERS UNIVERSITY | United States | Solution | 3 | VLS | $11.34 | $34.02 | MUMBAI AIR (SAHAR) | NEW YORK | AIR |
10
PART VI — EVIDENCE REGISTER
Indian Supplier Directory
All 5 Indian nivolumab exporters — complete list ranked by USD
KEY TAKEAWAY
This directory lists every Indian company that shipped nivolumab in 2025-Q4.
S FOR SUPPLIERS
Find yourself and your competitors. Compare shipment count, USD, and destination regions.
B FOR BUYERS
Search for potential Indian suppliers. Filter by dosage form and destination region.
| # | Supplier | City | Ships | USD | Dosage forms | Primary regions |
|---|---|---|---|---|---|---|
| 1 | DRREDDYS LABORATORIES LTD | Medchel Malkajgiri Dist | 2 | $291K | Injection | Europe |
| 2 | MC PHARMA DISTRIBUTORS | CHENNAI | 4 | $50K | Injection, Solution, Other | Asia |
| 3 | FINDLIFE PHARMACEUTICAL | SURAT | 1 | $80.36 | Injection | Americas |
| 4 | ENZENE BIOSCIENCES LTD | PUNE | 1 | $34.02 | Solution | Americas |
| 5 | MSN LABORATORIES PVT LTD | HYDERABAD | 1 | $8.19 | Solution | Europe |
10
PART VI — EVIDENCE REGISTER
Global Buyer Directory
All 4 global nivolumab importers — complete list ranked by USD
KEY TAKEAWAY
This directory lists every company that imported Indian nivolumab in 2025-Q4.
S FOR SUPPLIERS
Search for potential customers by country and dosage form.
B FOR BUYERS
Find your company and see which Indian supplier serves you.
| # | Buyer | Country | Ships | USD | Primary supplier | Dosage forms |
|---|---|---|---|---|---|---|
| 1 | COREX LLC | Russia | 2 | $291K | DRREDDYS LABORATORIE… | Injection |
| 2 | STATE TRADING ORGANIZATION PLC | Maldives | 2 | $25K | MC PHARMA DISTRIBUTORS | Injection |
| 3 | RUTGERS UNIVERSITY | United States | 1 | $34.02 | ENZENE BIOSCIENCES LTD | Solution |
| 4 | SARTORIUS STEDIM BIOOUTSOURCE LTD | United Kingdom | 1 | $8.19 | MSN LABORATORIES PVT… | Solution |
This report covers 9 2025-Q4 Nivolumab shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/nivolumab
Talk to our trade analyst
Need a custom nivolumab report or a deeper dive into any market? Our team is ready.
WhatsApp: +91 95950 78788 · transdatanexus.com
PHARMA TRADE INTELLIGENCE
Thank you for reading
This report is part of the TransData Nexus Pharma Trade Intelligence series, covering 366 pharmaceutical products exported from India.
Every figure is grounded in real commercial trade records — official customs filings and licensed databases. No surveys, no estimates, no fake data.
Need a custom report?
We can generate intelligence for any pharmaceutical product, any time period, any combination of source and destination countries.
Want deeper analysis?
Our team provides competitive intelligence, market entry strategy, and supply chain due diligence for pharma importers and exporters.
Scan for product page
WhatsApp: +91 95950 78788
Email: info@transdatanexus.com
Web: https://transdatanexus.com/pharmaceutical/nivolumab
© 2026 TransData Nexus. All rights reserved. This report is provided for informational purposes only.
Data sourced from official customs filings and licensed commercial trade databases.
Reproduction without permission is prohibited.
Explore the full Nivolumab product page
Live data, supplier directory, price trends, and trade route analysis